In response to the global resurgence of mpox, a viral disease caused by the orthopoxvirus family, researchers at the Icahn School of Medicine at Mount Sinai have made significant strides in developing potential treatments. Their study, recently published in Cell, focused on human monoclonal antibodies that target the viral protein A35. These antibodies were sourced from an individual previously infected with mpox and showed promising results in preventing death from the disease in mice. The study highlights the importance of understanding the human antibody response to key monkeypox virus antigens for improved public health strategies.
Mpox, similar to smallpox, spreads through close contact with infected individuals and manifests with symptoms like rash, enlarged lymph nodes, and fever. Despite being declared a public health emergency by the World Health Organization, effective treatments for the orthopoxvirus family have been lacking. The research by the Mount Sinai team sheds light on a potential avenue for addressing this gap by utilizing antibodies that target a conserved region on the viral protein A35.
The antibodies discovered in this study not only blocked viral spread in laboratory tests but also provided protection against severe disease and prevented death in rodents. Their binding to a highly conserved region across the orthopoxvirus genus and the broader poxvirus family indicates their potential as promising drug candidates for further testing in humans. By targeting a region that is shared among different viruses and resistant to mutations, these antibodies offer a novel approach to combatting orthopoxviruses.
The crystal structure of a human antibody bound to the mpox virus protein, as revealed in this study, provides valuable insights into the vulnerability of the virus. This structural understanding, coupled with immunological data on antibody responses to mpox infection, paves the way for advancing these antibodies into advanced preclinical testing. The research team is not only focused on the development of these antibodies as potential treatments but also on leveraging their findings to enhance the human immune response against mpox.
Moving forward, the researchers plan to conduct further safety and efficacy tests on the newly discovered antibodies while leveraging the structural and immunological insights gained from their study. The ultimate goal is to address the urgent need for effective treatments against orthopoxviruses and potentially pave the way for preventive or therapeutic interventions for mpox in humans. By capitalizing on the conserved nature of the target region on the A35 protein, these antibodies represent a significant step towards combating deadly viral diseases.
- Human monoclonal antibodies targeting the A35 protein have shown promise in preventing death from mpox in rodents.
- The conserved nature of the target region across the orthopoxvirus genus and poxvirus family makes these antibodies potential candidates for further drug development.
- Insights from the crystal structure of the antibody-virus protein complex provide a roadmap for future immunotherapy strategies.
- Leveraging both structural and immunological data can lead to enhanced human immune responses against mpox and related orthopoxviruses.
Tags: immunotherapy, biotech, monoclonal antibodies
Read more on genengnews.com